The clinical assessment of IVT-mRNA technology in the context of PRT includes the IVT-mRNA of the vascular endothelial growth factor (VEGF, NCT03370887) and the IVT-mRNA of CFTR (NCT03375047) [53], as well as IVT-mRNAs for myocardial infarction and heart failure (NCT03370887) [54] and for genetic lung disorders [55]. Here, VEGFA is linked to heart failure.